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p300/CBPGeﬁtinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor, approved for patients with
non-small cell lung cancer (NSCLC). In this report we demonstrate that geﬁtinib loaded PLGA nanoparticles
(GNPs), in comparison to geﬁtinib, exhibited higher anti-cancer activity on A549 lung carcinoma cells and
A431 skin carcinoma cells. Increased inhibition of pEGFR in both the cell types explains its higher anti-cancer
activity. Interestingly, geﬁtinib resistant, H1975 (T790M EGFR mutant) lung carcinoma cells was also found
to be sensitive to GNPs. Our data shows that GNPs hyperacetylate histone H3 in these cells, either directly or
indirectly, which may account for the augmented cell death. GNPs were proﬁcient in activating histone
acetyltransferases (p300/CBP), which in turn induces the expression of p21 and cell cycle arrest. Furthermore,
inhibition of histone acetyltransferases by garcinol results in alleviation of cell death caused by GNPs. In addition
to this, nuclear intrusion of GNPs results in the inhibition of NO production in nucleus, possibly through nuclear
EGFR, which might be responsible for preventing cell proliferation in resistant cells. To best of our knowledge,
we provide ﬁrst evidence that GNPs potentiate cell death by activating p300/CBP histone acetyltransferases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Tyrosine kinase inhibitors (TKIs) have proved themselves as potent
anti-cancer agents. TKIs such as geﬁtinib and erlotinib have been used
effectively to treat non-small cell lung cancer (NSCLC). Geﬁtinib selec-
tively inhibits EGFR (ErbB1) tyrosine kinase and has a 200 fold greater
afﬁnity for ErbB1 as compared to ErbB2 [1]. Themajor hindrance to this
therapy is the resistance which arises due to mutations in EGFR. It has
been reported earlier that 50% of the resistant cells have a secondary
mutation in EGFR which involves the substitution of threonine at
position 790 with methionine (T790M) [2,3]. Threonine 790 is located
at the entrance to a hydrophobic pocket behind the ATP binding cleft
and thus it is an important determinant of inhibitor speciﬁcity in the
protein kinase. Substitution of a bulky methionine residue at this
position results in steric interference with binding of geﬁtinib [4]. But
recent studies have showed that T790M mutants retain low nano-
molar afﬁnity for geﬁtinib and the drug resistance in these mutants
has been proposed to be due to the restoration of ATP afﬁnity to the
level of wild type levels [5]. An effective cancer therapy is yet to be
designed so as to overcome this resistance.
Nanotechnology has opened up various opportunities in the ﬁeld of
drug delivery. Drug loaded nanoparticles show prolonged systemic
circulation lifetime, sustained drug release kinetics and better tumor
penetration [6,7]. Various nanoparticle based systems such as liposomes,
polymeric nanoparticles, dendrimers etc. have been used for drugl rights reserved.delivery. Polymeric nanoparticles contain a solid polymer ﬁlled core
which is more suitable for carrying water insoluble drugs [8]. Various
polymers have been used to prepare drug loaded nanoparticles with
poly (lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) being
the most frequently used ones. Currently liposomes are the sole nano-
particle based drug delivery platform which have reached the clinical
trial stage [8].
Recent studies have highlighted the role of nanotechnology in over-
coming drug resistance. Enhanced uptake and retention of doxorubicin
in multi-drug resistant (MDR) breast cancer cells have been observed
using polymer-lipid hybrid nanoparticle system [9]. In another study,
a group has developed gold-doxorubicin nano-conjugate system to
overcome MDR [10]. Another strategy for overcoming MDR has been
designed by using functional paclitaxel nanomicelles and delivering
them by oral route. Signiﬁcant antitumor activity was observed in
xenografted resistant MCF-7/Adr cancers in mice, which was compara-
ble to intravenous administration [11]. A different group has reported
that mesoporous silica nanoparticle (MSNP) system can be used as a
new approach to overcome multi drug resistance (MDR). These
MSNPs were used to deliver siRNA to speciﬁcally knockdown the
gene expression of drug exporter which is the main culprit behind
doxorubicin resistance in KB-V1 cells [12]. Co-formulation of curcumin
and doxorubicin has also been used to overcome MDR in K562 chronic
myeloid leukemia cells. Curcumin helps to retain doxorubicin in nucle-
us for longer time and it inhibits the expression of MDR1 and Bcl2
which are responsible for the longevity of leukemia cells [13].
Nanoparticles, when in contact with biological ﬂuids, have been
suggested to be covered by a selected group of bio-molecules which
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Fig. 1. (A) Zetasizer and zetapotential of GNPs (B) transmission electron microscopic
image of geﬁtinib encapsuled PLGA nanoparticles: The sample was prepared as
mentioned in experimental methods. Sample was loaded on formvar coated copper
grid and allowed to dry before size determination. Average size of nanoparticles was
180±20 nm.
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tions may further determine the biological activity of nanoparticles.
Thus, we designed the present study to understand the molecular
interactions of GNPs with cells having different EGFR expression levels
as well as cells with mutant EGFR.
2. Experimental section
2.1. Synthesis of PLGA nanoparticles encapsulating geﬁtinib
In our study, we encapsulated geﬁtinib in biocompatible polymer
PLGA by using oil in water emulsion technique. This is a suitable
method to encapsulate hydrophobic drugs such as geﬁtinib wherein,
both drug and the biodegradable polymer are dissolved in organic
solvent such as chloroform and then the resulting organic oil phase
is emulsiﬁed in aqueous solution containing appropriate emulsiﬁer.
PVA is a co-polymer of vinyl acetate and vinyl alcohol and is the
most commonly used emulsiﬁer due to its exceptional interaction
with PLGA surfaces [15]. The volatile solvent is removed by stirring
the nanoparticle solution under vacuum [16]. PLGA is the most widely
studied matrix of biodegradable micro-particles and is being used ex-
tensively in numerous pharmaceutical formulations like cyclosporin
[17] and ellagic acid [18]. PLGA (Sigma Aldrich) and geﬁtinib in
equal ratio were dissolved in 1 ml chloroform. Oil in water emulsion
was formed by emulsifying the polymer-drug solution in 5 ml of 2.5%
aqueous PVA (Sigma Aldrich) solution by sonication on an ice bath for
5 min. The emulsion was stirred overnight and then for 2 h under
vacuum to remove chloroform. The nanoparticles were then obtained
from the solution by centrifugation at 30,000 rpm for 30 min at 4 °C.
The nanoparticles in the pellet form were then re-suspended in pro-
teomic grade water to remove any excess of PVA. This was repeated
ﬁve times to ensure complete removal of PVA and unencapsulated
drug. The amount of drug in supernatant obtained after each washing
was quantiﬁed using HPLC. PLGA nanoparticles encapsulating
6-coumarin were also synthesized by similar procedure.
2.2. Characterization of geﬁtinib nanoparticles
GNPs were analyzed under TEM (FEI TF-20) for size determination.
Brieﬂy, the stock solution of GNPs synthesized by the above method
was diluted in DMEM (Sigma Aldrich) medium (so as to reach a
concentration of 8 μM) supplemented with 10% Fetal Bovine Serum
(FBS) followed by sonication. 2 drops of the solution were dropped
onto carbon coated copper grids (from Ted Pella INC) and kept for dry-
ing. The dried sample was analyzed under the microscope at 200 kV.
Dynamic light scattering for characterization of hydrodynamic size of
GNPs dispersed in DMEM medium supplemented with 10% FBS was
performed on Nano-ZS, Malvern Instruments, Malvern, UK, taking the
average of 5 measurements. Zetapotential was also measured to deter-
mine the amount of aggregation of particles.
2.3. Drug encapsulation and drug release efﬁciency
To determine the amount of drug encapsulated within the
nanoparticles, 3 mg of nanoparticles was extracted with 1 ml metha-
nol for 16 h. The extract was then centrifuged at 14,000 rpm for
20 min. The supernatant was analyzed for concentration of geﬁtinib
using Shimadzu HPLC system. A C-18 column was used. The mobile
phase consisted of 0.02 M dipotassium hydrogen ortho phosphate
and methanol in the ratio of 10:90 v/v delivered at a ﬂow rate of
1 ml/min. 20 μl of methanol extract was injected and geﬁtinib was
quantiﬁed by UV detection at 246 nm. Retention time of geﬁtinib was
evaluated.
Drug release from nanoparticles was determined in Phosphate
Buffer Saline (PBS, 0.15 M, pH 7.4) containing 0.1% Tween-80. The sus-
pension of nanoparticles was placed in several 1.5 ml centrifuge tubesand kept in water-bath shaker set at 100 rpm and 37 °C. At particular
intervals, centrifuge tubes were retrieved from the water-bath and
centrifuged at 12,000 rpm. The supernatant was then analyzed for
geﬁtinib concentration by HPLC system. Amount of geﬁtinib taken up
by the cells was also quantiﬁed by using HPLC (Supplementary Fig. S6).
2.4. Cell culture
A549 human lung carcinoma, A431 human epithelium carcinoma and
H1975 T790Mmutant cells were obtained fromATCCUSA. The cells were
cultured in DMEM and RPMI containing 10% FBS and 1% penicillin–
streptomycin. DMEM, RPMI and FBS were obtained from Sigma Aldrich.
Antibiotic was purchased from Invitrogen. Cell cultures were maintained
in ﬂasks under standard conditions: incubation at 37 °C and 5% CO2. All
the subcultures were used prior to passage 15. Cells were routinely pas-
saged using 0.25% trypsin/0.1% EDTA. For treatment, cells were cultured
in the presence of increasing concentrations (10 nM–100 μM for MTT
and 8 μM for western blotting) of Geﬁtinib and GNPs for 48 h.
2.5. Viable cells were assessed using MTT assay
The number of viable cells was assessed using MTT assay. Brieﬂy,
cells were seeded at 5000 cells per well in 96-well plates in a total vol-
ume of 100 μl and incubated for 24 h. Cells were then exposed to
Geﬁtinib and GNPs (10 nM–100 μM) for the times indicated. For color
development, 0.5% of the dye solution was added to each well, plates
were incubated at 37 °C for 4 h, and 300 μl of DMSO was added to
each well to dissolve the formazan crystals. Absorbance was recorded
using a microplate reader (Bio-TEK, Winooski, Vermont) at a wave-
length of 570 nm. Cell viability was expressed as the percentage
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which represented 100% viability. Experiments were carried out in trip-
licate. Cell viability assay was also performed with PLGA nanoparticles
with no drug encapsuled within it (Supplementary Fig. S7).2.6. Immunoﬂuorescent microscopy and nanoparticle trafﬁcking within
the cells
The intracellular localization of nanoparticles within the cell types
was studied using 6-coumarin loaded PLGA nanoparticles which
were synthesized as described before. The cells were treated withFig. 2. Cytotoxic effect of geﬁtinib and GNPs: (A) A549 cells treated for 24 h (B) 48 h (C) A43
were checked for their metabolic status by MTT assay. Untreated cells were considered
Mean±SEM (n=3); ***pb0.001, **pb0.01, *pb0.05 Vs geﬁtinib control; ###pb0.001, ##pnanoparticles for 30 min. Thereafter the cells were observed under
NIKON inverted microscope at the magniﬁcation of 40×.
For immunoﬂuroscence cells were grown on 6-well plates for 24 h
and were incubated with geﬁtinib and GNPs for the next 48 h. After
the treatment, cells were washed thrice with chilled PBS and then
were ﬁxed in 2.5% glutaraldehyde for 10 min at room temperature.
The ﬁxed cells were permeabilized using 0.1% Triton X-100 and thereaf-
ter washed with PBS to remove excess of Triton X-100. Cells were
blocked with 1% BSA for 45 min and then incubated with primary anti-
body overnight at 4 °C. After incubation, cells were washed with PBS
and further incubated with secondary antibody tagged with Texas
Red. Nuclear marker, 4′, 6-diamidino-2-phenylindole, dihydrochloride1 cells were treated for 24 h (D) 48 h, (E) H1975 cells treated for 24 h (F) 48 h and then
as the control group and represented 100% viability. All values are represented as
b0.01, #pb0.05 Vs GNP control.
Fig. 3. (A) Internalization of 6-coumarin loaded PLGA nanoparticles: Homing of 6-coumarin loaded nanoparticles in (A) A549 cells (B) A431 cells and (C)H1975 cells. The cells were treat-
edwith PLGAnanoparticles loadedwithﬂuorescent dye, 6-coumarin for 30 min andwere then observed under invertedmicroscope. The arrows depict the presence of 6-coumarin loaded
PLGA nanoparticles in the cells. The width of arrow represents the amount of 6-coumarin nanoparticle uptake such that the uptake was maximum in A431 cells andminimum in H1975
cells. (B) Inhibition of pEGFR levels by geﬁtinib and GNPs: Western blots for pEGFR and EGFR in A431 and A549 cells which were treated with geﬁtinib and geﬁtinib nanoparticles are
shown along with the densitometric quantiﬁcation. All values are represented as Mean±SEM (n=3); ***pb0.001 Vs Control; ###pb0.001, #pb0.05 Vs Gef.
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visualized under NIKON inverted microscope. The primary antibodies,
Texas red tagged secondary antibodies and DAPI were obtained from
Santa Cruz Biotechnology.
2.7. Western analysis
A549, A431 and H1975 cells were plated for western analysis. Cells
were treated with 8 μM geﬁtinib and GNPs for 48 h. Protein isolation
was performed as described before by [19]. Brieﬂy, treated cells were
washed with chilled PBS. The cells were then scraped in lysis buffer and
sonicated. The proteins were separated by centrifugation at 10,000 rpm
for 8 min. Similar study was performed on H1975 cells in which HAT
was inhibited by using garcinol. The cells were pre-treated with 10 μM
garcinol and then treated with 8 μM GNPs. Protein estimation wasFig. 4. (A) GNP treated A431 and H1975 cells show increased expression of histone H3 ace
quantitatively assessed by densitometric analysis. H3 total loading control is also shown. Al
were treated with 8 μM geﬁtinib and GNPs and then assessed for change in expression of p3
SEM (n=3); ***pb0.001: **pb0.01 Vs Control (C): H1975 cells were treated with 8 μM ge
loading control is also shown. All values are represented as Mean±SEM (n=3); ***pb0.
H1975 cells: Cells were treated with 8 μg/ml geﬁtinib and GNPs and then assessed for chan
as Mean±SEM (n=3); ***pb0.001: **pb0.01 Vs Control; and (E) immunoﬂuroscence micro
Red labeled secondary antibody where a: control untreated cells, b: Geﬁtinib treated cells, c:
nucleus. Red dye represents p21 and blue dye represents the nucleus.performed using Lowry's method. The samples were then prepared for
SDS-PAGE and then loaded on polyacrylamide gel. The proteins were
transferred on a PVDF membrane which was incubated in presence of
anti-pEGFR, anti-EGFR, anti-iNOS, anti-pNF-κB, anti-p300, anti-CBP,
anti-tubulin, anti-p21, and anti-Actin (1:1000 dilution; obtained from
Santa Cruz Biotechnology) overnight. The antigen antibody complex
was detected using HRP-coupled secondary antibodies (Santa Cruz Bio-
technology). Speciﬁc bandswere detected by chemiluminescence, and vi-
sualization was performed by exposure of the membranes to hyperﬁlm
(GE Healthcare).
2.8. Statistical analysis
Results were expressed as the mean value±SEM. Comparison of
mean values between various groups was performed by one waytylation: Cells were treated with 8 μM geﬁtinib and GNPs. The level of acetylation was
l values are represented as Mean±SEM (n=3); ***pb0.001 Vs Control; (B): A431 cells
00 and CBP. Tubulin loading control is also shown. All values are represented as Mean±
ﬁtinib and GNPs and then assessed for change in expression of p300 and CBP. Tubulin
001: **pb0.01 Vs Control (D) induction of p21, cell cycle arrest protein, in A431 and
ge in expression of p21. Actin loading control is also shown. All values are represented
scopy: H1975 cells were immuno-labeled with primary antibody against p21 and Texas
GNP treated cells. The cells were counterstained with DAPI which speciﬁcally stains the
Fig. 4 (continued).
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isons by turkey's test. P-valueb0.05 is considered to be signiﬁcant.
3. Results and discussion
3.1. Characterization, drug loading and release efﬁciency of geﬁtinib
loaded PLGA nanoparticles
Weencapsuled geﬁtinibwithin PLGA (50:50) by using poly-vinyl al-
cohol (PVA) as an emulsiﬁer. These nanoparticleswere then thoroughly
characterized to determine their size and surface potential. GNPs
exhibited negative (−22.9 mV) surface potential and the PdI value
was found to be 0.362 as shown in Fig. 1A. The high negative surface
charge ensures well dispersed and less aggregated nanoparticles.
GNPs observed under transmission electron microscope were almost
spherical and uniformly distributed (Fig. 1B). The average size of GNPs
was found to be 180±20 nm.
To authenticate the presence of geﬁtinib within the nanoparticles,
geﬁtinib was extracted out of NPs and the extracted product was
analyzed using HPLC. We used methanol as our choice of solvent to
mine geﬁtinib out of PLGA nanoparticles. Methanol is known to
extract hydrophobic drugs out of polymers, without dissolving the
polymer [20]. The chromatogram obtained was compared with
geﬁtinib standard HPLC chromatogram (Supplementary Fig. S1). The
coincident retention times validated the presence of geﬁtinib within
the PLGA nanoparticles. High loading capacity is an important requi-
site for a successful nanoparticle based drug delivery system [21].
We ensured that the drug was totally encapsulated within PLGA
by washing it several times with proteomic grade water. The
nanoparticles were then settled down by centrifugation and the su-
pernatant was analyzed by HPLC for residual geﬁtinib concentration.
After ﬁve subsequent washes it was found that the concentration of
geﬁtinib was beyond the detection limit in the supernatant (Supple-
mentary Fig. S2) and the nanoparticles obtained were then evaluated
for entrapment efﬁciency. HPLC analysis exhibited successful loadingof geﬁtinib within PLGA nanoparticles, with loading efﬁciency of 60%
(Supplementary Fig. S3). Such high loading minimizes the amount of
carrier required. Encapsulated drugs need to be released from
polymer matrix so as to meet the therapeutic goal of the drug [22].
Various factors control the release rates of the drug including particle
size and the porosity. Thus to determine the therapeutic efﬁcacy of
drug loaded nanoparticles, it becomes immensely important to deter-
mine the drug release pattern. In vitro release of geﬁtinib from NPs
was carried out by dissolving 3 mg of GNPs in 3 ml of PBS (0.01 M,
pH 7.4) containing 0.1% Tween 80. A sustained release pattern of
geﬁtinib from PLGA nanoparticles was observed (Supplementary
Fig. S4). We minimized the initial burst release of drug from
nanoparticles by washing the GNPs several times with water before
performing the in vitro release studies. Approximately 65% and 99%
of encapsulated drug was released in 24 and 48 h respectively. The
slow and steady release of drug ensure maximum efﬁcacy of GNPs
over time.
3.2. Geﬁtinib nanoparticles exhibit enhanced cytotoxic effects in vitro
Cytotoxic effects of nanoparticles have been correlated with the
receptors present in the cells [23]. Anti-cancer activity of geﬁtinib
has been evaluated on panel of cells and the sensitivity of these
cells towards geﬁtinib was correlated with dependence of the cell
on EGF receptor pathway for survival and proliferation [24]. To dem-
onstrate the enhanced anti-cancer activity of geﬁtinib loaded PLGA
nanoparticles we selected three different cells with different EGFR
expressions: A549 lung carcinoma cells (wild type EGFR), A431 skin
carcinoma cells (EGFR over-expressing) and H1975 lung carcinoma
cells (mutation in T790M position of EGFR). We investigated the
proliferation and metabolic status of the cells by the MTT assay.
A549 adenocarcinoma cells express wild type EGFR and show inter-
mediate responsiveness towards geﬁtinib. Low responsiveness of
A549 can be due to high levels of phosphorylated Akt even without
ligand stimulation [25]. Suppression of E2F-1 expression and
Fig. 5. (A) Effect of garcinol (HAT inhibitor) on anti-cancer activity of GNPs in H1975 cells: Cells were treated with 10 μM garcinol and 80 μM GNPs for 48 h and then assessed for
cell viability by MTT assay. (B) Expression of p300, CBP and H3 acetylation in GNP treated H1975 cells in the presence and absence of garcinol (HAT inhibitor): Cells were treated
with 10 μM garcinol and 8 μMGNPs for 48 h and then assessed for change in expression of p300, CBP and H3 acetylation. Tubulin and total H3 loading control for p300/CBP and H3
acetylation respectively is also shown along with densitometric analysis. (C) Expression of p21 in GNP treated H1975 cells in the presence and absence of garcinol (HAT inhibitor):
Cells were treated with 10 μM garcinol and 8 μM GNPs for 48 h and then assessed for change in expression of p21. All values are represented as Mean±SEM (n=3); ***pb0.001;
**pb0.01: Vs Control.
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Fig. 5 (continued).
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geﬁtinib in A549 cells [26]. Figs. 2(A) and (B) demonstrate the dose
dependent decrease of MTT signal in A549 cells at an interval of 24
and 48 h respectively. IC50 value was calculated for both 24 (geﬁtinib:
>100 μM and GNP: 57.29 μM) and 48 h (geﬁtinib: 56 μM and GNP:
30.42 μM). The IC50 values reﬂect that GNPs exert a much higher cy-
totoxic effect as compared to geﬁtinib. The difference between the
IC50 values was signiﬁcant enough to rank GNP as more potent in
inhibiting the growth of lung cancer cells as compared to geﬁtinib.
A431 cells, which over express EGFR, also showed a signiﬁcant
reduction in the IC50 value when treated with GNPs (IC50 values
after 24 h geﬁtinib: 82.2 μM and GNP: 48.8 μM and 48 h geﬁtinib:
48.19 μM and GNP: 27.11 μM) as shown in Figs. 2(C) and (D). The re-
duction was almost 2 folds when compared to IC50 calculated after
geﬁtinib treatment, for both the time intervals. This observation can
be attributed to the fact that nanoparticles are taken up much more
easily and efﬁciently as compared to geﬁtinib. Faster uptake ensures
more time for geﬁtinib to interact with macromolecules within the
cell. Thus GNPs prove to be more effective in limiting the growth of
cancer cells.
Patients with EGFR-sensitive mutations do not respond well to re-
peated geﬁtinib treatment due to acquired resistance, caused by the
secondary mutations such as T790M in the EGFR kinase domain [27].
Therefore, to address this problem we checked the efﬁcacy of GNPs
on H1975 geﬁtinib resistant cells which possess T790M (exon 20)
and L858R (exon 21) mutation in EGFR. Interestingly, H1975 cells
which are resistant to geﬁtinib showed sensitivity towards the encap-
sulated form of the drug (Figs. 2(E) and (F)). H1975 cells harbor two
mutations in EGFRwhich inhibit the binding of geﬁtinib to the receptor
sites. These mutations activate Akt and STAT signalling pathways for
cell survival [28]. Nanoscale particles have an appropriate size which
enables them to engage with the cellular machinery, in much the
samemanner as biomolecules and proteins [29]. Nanoparticles possess
high surface area thereby increasing the bioavailability of geﬁtinib
within the cells. This may account for the higher cell death caused byGNPs. GNP induced cell death is maximum at the 72 h interval in
H1975 cells (Supplementary Fig. S5) as compared to 24 and 48 h in
A431 and A549 cells. To account for this delay in action, we compared
the rate of uptake of GNPs by the cells.
3.3. Cellular uptake of geﬁtinib nanoparticles
A number of studies have emphasized on the interaction between
nanoparticles (NPs) and biological systems so as to understand their
systemic and cellular trafﬁcking. Role of NP size in their uptake has
recently been elaborated and it has also come up that the kinetics of
uptake of same nanoparticles varies in different cells. Cells which
are not specialized in phagocytosis also take up nanoparticles with
different internalization efﬁciencies [30]. Moreover recent reports
suggest that cellular uptake of nanoparticles also depends upon
the phase of the cell cycle [31]. Higher sensitivity of the cells
toward GNPs, as displayed by MTT assay, suggests that the cellular in-
ternalization might be of key consideration for their enhanced
anti-cancer activity. Nanoparticles have an easy access to the internal
structures of the cell such as nucleus. To determine the uptake capac-
ity of GNPs in different cells, we encapsulated PLGA nanoparticles
with ﬂuorescent dye 6-coumarin as described before by Davda et al.
[32]. The cells were exposed to these nanoparticles for 30 min and
then visualized under ﬂuorescent microscope. Interestingly, the
level of ﬂuorescence corroborated well with the cell viability data
such that A431 cells which underwent maximum cell death showed
maximum uptake of nanoparticles. Close observation of the cells
showed that the nanoparticles accumulated on the nuclear mem-
brane (Fig. 3A). Least ﬂuorescence could be observed in H1975 cells
which also showed minimum cell death. This indicates a relationship
between the uptake of nanoparticles and the amount of cell death in
different cells.
3.4. Geﬁtinib nanoparticles potentiate the inhibition of pEGFR
EGFR transduces growth and survival signals in lung cancer cells
and therefore it became a rational target for cancer therapy. It is
well established that geﬁtinib inhibits the phosphorylation of trans-
membrane EGFR by binding to the ATP binding site of EGFR tyrosine
kinase. A recent in vitro study demonstrated that PC9 cell line was
most sensitive to the effect of geﬁtinib, out of the various cells tested,
when assayed for EGFR phosphorylation, which is required for its
survival and proliferation [24]. Thus to validate the higher efﬁcacy
of nanoparticles, we compared the expression of pEGFR, in A549
and A431 cells, after treatment with both geﬁtinib and GNPs. Our
data shows that the level of pEGFR signiﬁcantly decreased as com-
pared to untreated control cells as well as geﬁtinib treated cells in
both the cell types (Fig. 3B). Decrease in the level of pEGFR results
in the prevention of ligand induced receptor activation and blocks
signalling of EGFR dependent pathways for cell growth. A more
pronounced decrease in phosphorylation by GNPs indicated higher
potency of GNPs over geﬁtinib. This corroborates well with our cell
viability data which also depicts that GNPs have more persuasive
anti-cancer activity when compared with geﬁtinib.
3.5. Geﬁtinib nanoparticles hyperacetylate histone H3 via histone
acetyltransferases p300/CBP and further potentiates p21 expression
EGFR is placed in direct contact with chromatin/DNA and it has
been speculated that EGFR has transcription regulatory functions.
Lin et al. have proposed that EGFR might function as a transcription
factor to activate genes required for proliferation [33]. Previous
studies have shown that both EGF and EGFR form complexes with
chromatin, especially in transcriptionally active regions [34]. Histone
modiﬁcations have been linked many a times with the development
of drug resistance [35,36]. There is emerging evidence which links
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Fig. 6. (A) Inhibitionof iNOS expressionbyGNPs:GNPs successfully inhibited iNOS andNF-κBexpression inA431 cells as depictedbydensitometric quantiﬁcationofwesternblots. (B) Likewise,
GNPs inhibited the expression of iNOS and NF-κB in geﬁtinib resistant H1975 cells. Tubulin loading control is also shown. All values are represented as Mean±SEM (n=3); ***pb0.001:
**pb0.01 Vs Control. (C) H1975 cells were immunostained for iNOS where a: control untreated cells, b: Geﬁtinib treated cells, and c: GNP treated cells. The cells were counterstained with
DAPI which speciﬁcally stains the nucleus. Red dye represents iNOS and blue dye represents the nucleus. (D) Expression of iNOS in GNP treated H1975 cells in the presence and absence of
garcinol (HAT inhibitor): Cells were treated with 10 μM garcinol and 8 μM GNPs for 48 h and then assessed for change in expression of iNOS. Tubulin loading control for iNOS is also shown
along with densitometric analysis.
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to cisplatin chemotherapy in lung cancer [37]. Thus to evaluate
whether any epigenetic mechanism was involved in potentiating
the activity of GNPs, so as to overcome geﬁtinib resistance, we
checked for alterations in histone modiﬁcations in A431 and H1975
cells treated with geﬁtinib and GNPs. Various histone modiﬁcations
were checked but we did not ﬁnd any signiﬁcant changes in phos-
phorylation and methylation levels of histone H3 (data not shown)
except for acetylation levels. We found that both A431 and H1975
cells treated with geﬁtinib showed signiﬁcantly decreased levels of
histone H3 acetylation. On the contrary, GNPs showed a complete re-
versal as the histone H3 acetylation levels increased considerably in
cells treated with GNPs (Fig. 4A). Histone deacetylase inhibitors
such as trichostatin A have been reported to induce hyperacetylation
of histone and induces G1 cell cycle arrest [38]. Histone deacetylation
inhibitors are widely recognized as promising targets for cancer
therapy. The ability of GNPs to hyperacetylate histone H3 further sig-
nalled towards the elevated effectiveness of nanoparticles in limiting
the growth of cancer cells.
The correlation between histonemodiﬁcations and tumorigenesis is
well documented. But emerging evidence suggests another role of acet-
ylation, as a protein posttranslational modiﬁcation, which also plays a
critical role in cell fate and tumorigenesis. For instance, the activities
of the tumor suppressors, p53 and FOXO3a are both reported to be reg-
ulated by their acetylation status [39]. We checked the role of histone
acetylases (p300/CBP) and found that the level of p300 and CBP
acyltransferases increased signiﬁcantly in cells treated with GNPs as
compared to untreated and geﬁtinib treated cells (Figs. 4B,C). This sug-
gests that GNPs were able to activate histone acetyltransferases p300/
CBP which resulted in hyperacetylation of histone H3.
p300 and CBP also participate at various stages of the p53 response
[40]. It has also been known that HATs induce a signiﬁcant increase in
the expression of p21 [41,42], which is involved in arresting the cell
cycle in the G1 phase. Liu et al. have suggested that activity of p300/
CBP correlates with activity of p53 to induce p21 expression in H1299
cells. They have demonstrated that inhibition of p300/CBP by siRNA sig-
niﬁcantly reduces the ability of p53 to induce p21 [43]. We found a
sharp increase in the expression of p21 in cells treated with GNPs
(Fig. 4D). Moreover, we also evaluated the sub-cellular localization of
p21 in H1975 cells by immunoﬂuroscence (Fig. 4E). A signiﬁcant
increase in the red ﬂuorescence was observed in cells treated with
GNP. This further supports the immunoblot and signiﬁes a substantial
increase in the expression of p21. Increase in the level of cell cycle arrest
proteinmay also explain the potentiation of anti-cancer activity of GNPs
in drug resistant cells. Thus it can be very well correlated that the
increased levels of H3 acetylation involving HATs and concomitant
increase in expression of p21, further lead to cell death in A431 and
H1975 mutant cells. Certain reports suggest that EGF receptor signals
are not always responsible for the sensitivity of cells to geﬁtinib [44].
Recent reports have associated the cytotoxicity of geﬁtinib with de-
crease in telomerase activity in MDA-MB231 breast cancer cells [45].
Moreover, geﬁtinib has also been reported to inhibit the proliferation
of pancreatic cancer cells by arresting cell cycle [46]. Our observations
of histone hyperacetylation very well explain the plausible mechanism
behind the EGFR independent role of geﬁtinib induced cell death.
3.6. Inhibition of HATs (p300/CBP) by garcinol prevents geﬁtinib
nanoparticles induced cell death
Further, to validate the role of histone hyperacetylation in enhanc-
ing the anti-cancer activity of GNPs, H1975 cells were incubated in the
presence of garcinol, a potent HAT inhibitor [47] and evaluated the an-
ticancer activity of GNPs. As shown in Fig. 5A, anti-cancer activity of
GNPs was considerably reduced in cells treated with garcinol along
with GNPs. GNPs alone caused signiﬁcant cell death but in cells
supplemented with garcinol, GNPs were rendered ineffective. Thisdata further conﬁrms our earlier observation that histone acetylation
plays a critical role in escalating the anti-cancer activity of GNPs.
We also checked the alteration in the levels of p300, CBP and H3
acetylation in H1975 cells treated with GNPs in the presence and
absence of garcinol. The cells treated with both garcinol and GNPs
expressed lower levels of p300/CBP as well as H3 acetylation in
comparison to only GNP treated cells as shown in Fig. 5B. Therefore,
inhibition of histone acetyltransferases by garcinol leads to consider-
able decrease in the anti proliferative activity of GNPs. This further
conﬁrms, that increase in H3 acetylation levels is indeed behind the
enhanced anti-cancer activity of GNPs. Moreover, the repressed levels
of p21 in cells treated with garcinol and GNP (Fig. 5C) also supported
our earlier inferences that GNPs exhibit higher anti-cancer activity
due to activation of histone acetyltransferases (p300/CBP) which
further activates cell cycle arrest protein p21.
3.7. Attenuation of the expression of nuclear EGFR dependent iNOS by
geﬁtinib nanoparticles
Taken together, we provide convincing evidence that the drug
when encapsuled in nanoparticles not only shows more potency but
is also competent enough to overcome the drug resistance, as
depicted by the decrease in cell viability of H1975 cells (Figs. 2(E)
and (F)). Certain reports indicate the nuclear translocation of integral
receptors present on the plasma membrane [33]. Various functions of
these receptors have been anticipated of which transcriptional regu-
lation is ﬁrst on the list. Some reports have also showed that these
receptors may act as stop signals when they translocate to the
nucleus [48]. Out of the many growth factor receptors, the presence
of nuclear EGFR is most widely recognized. Nuclear accumulation of
EGFR has been associated with enhanced DNA synthesis and cell pro-
liferation. Studies have elaborated the mechanism by which nuclear
EGFR, which lacks DNA binding domain, regulates gene expression.
STAT3 physically associates with nuclear EGFR and this complex
further interacts with the iNOS promoter thereby activating iNOS
gene expression and promoting cell growth [49]. Recent reports sug-
gest that suppression of STAT3 activity may impart geﬁtinib sensitiv-
ity to NSCLC [50]. Increase in H3 acetylation levels by GNPs hinted
towards possible involvement of iNOS in preventing cell growth as
various reports have highlighted the role of HDAC inhibitors in
decreasing NF-κB and subsequently, iNOS levels [51,52]. In both
A431 and H1975 cells treated with GNPs, we found a signiﬁcant re-
duction in the expression of iNOS as compared to geﬁtinib. In addition
to this, NF-κB, which binds and activates the promoter of iNOS, was
also found to be inhibited in GNP treated cells (Fig. 6A). This provides
a plausible mechanism for higher cell death observed by treatment of
GNPs.
In H1975 mutant cells, geﬁtinib is unable to cause any decrease in
the expression of iNOS, whereas GNP treated cells show signiﬁcant
decrease in the expression of iNOS (Fig. 6B). iNOS is responsible for
the production of nitric oxide (NO) which further assists the cells in
proliferation. Subcellular localization of iNOS by immunoﬂuroscence
also corroborates the results observed in immunoblot analysis. Red
ﬂuorescence, which signiﬁes the presence of iNOS, signiﬁcantly re-
duces in GNP treated cells (Fig. 6C). Further, the expression of iNOS
was also checked in garcinol treated cells. As shown in Fig. 6D,
GNPs signiﬁcantly lowered iNOS expression in H1975 cells, which
was reversed by subsequent treatment with garcinol. Thus, histone
acetylation levels directly or indirectly inﬂuence the levels of iNOS.
4. Conclusion
Here we propose a putative pathway (Fig. 7) which justiﬁes the en-
hanced potency of GNPs. GNPs not only inhibit plasma membrane EGFR
but also its nuclear localization results in hyperacetylation of histone H3
by activation of p300/CBP (histone acetyltransferases). The activated
Fig. 7. Graphical representation of summary of this report.
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main, to interact with chromatin structure and activate various genes
responsible for cell death. In addition, GNPs inhibit the expression of nu-
clear EGFR dependent iNOS which prevents cell proliferation. Further
studies are required to elucidate on how nuclear localization of tyrosine
kinase inhibitor (geﬁtinib) renders a histone acetyltransferases (HAT)
activator and enhances its anti-cancer activity; understanding of which
will be of profound clinical signiﬁcance.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.01.029.
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